The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)


Chemical Compound Review

AC1L2HBP     2-[4,10- bis(carboxylatomethyl)-7- [(2R,3R)...

Synonyms: AR-1J1141
This record was replaced with 72058.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


High impact information on 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


Chemical compound and disease context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


Biological context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


Anatomical context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


Associations of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid with other chemical compounds


Gene context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

  • CONCLUSION: Contrast-enhanced CT with 1 mol/L gadobutrol in a dose of 2 mmol/kg BW resulted in an excellent vascular and parenchymal enhancement in most vascular regions and parenchymal organs similar to an equivalent volume of 300 mg/mL iodinated contrast media [9].
  • The purpose of this study was to compare moving-table three-dimensional contrast-enhanced magnetic resonance angiography (CE MRA), using 1.0-mol gadobutrol, with intra-arterial digital subtraction angiography (i.a. DSA) for evaluation of pelvic and peripheral arteries in patients with peripheral arterial occlusive disease [22].

Analytical, diagnostic and therapeutic context of 2-[4,10-bis(carboxymethyl)-7-[(1R,2S)-2,3-dihydroxy-1-methylol-propyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid


  1. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Tombach, B., Bremer, C., Reimer, P., Kisters, K., Schaefer, R.M., Geens, V., Heindel, W. Radiology. (2001) [Pubmed]
  2. Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma. Kawai, J., Takahashi, M., Kato, N., Takashima, K., Miyazawa, T. Magnetic resonance imaging. (1999) [Pubmed]
  3. Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent Gadobutrol. Hofmann, B., Fischer, C.O., Lawaczeck, R., Platzek, J., Semmler, W. Investigative radiology. (1999) [Pubmed]
  4. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Tombach, B., Bremer, C., Reimer, P., Schaefer, R.M., Ebert, W., Geens, V., Heindel, W. Investigative radiology. (2000) [Pubmed]
  5. Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials. Frigeni, V., Miragoli, L., Grotti And, A., Lorusso, V. Investigative radiology. (2001) [Pubmed]
  6. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Tombach, B., Benner, T., Reimer, P., Schuierer, G., Fallenberg, E.M., Geens, V., Wels, T., Sorensen, A.G. Radiology. (2003) [Pubmed]
  7. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Essig, M., Lodemann, K.P., Le-Huu, M., Brüning, R., Kirchin, M., Reith, W. Investigative radiology. (2006) [Pubmed]
  8. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Pintaske, J., Martirosian, P., Graf, H., Erb, G., Lodemann, K.P., Claussen, C.D., Schick, F. Investigative radiology. (2006) [Pubmed]
  9. 1-molar gadobutrol as a contrast agent for computed tomography: results from a comparative porcine study. Kalinowski, M., Kress, O., Wels, T., Alfke, H., Klose, K.J., Wagner, H.J. Investigative radiology. (2003) [Pubmed]
  10. Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. Goyen, M., Herborn, C.U., Vogt, F.M., Kröger, K., Verhagen, R., Yang, F., Bosk, S., Debatin, J.F., Ruehm, S.G. Journal of magnetic resonance imaging : JMRI. (2003) [Pubmed]
  11. Pulmonary resorption of inhaled gadobutrol in an animal model: usage to determine lung diffusion in MRI examinations. Hirsch, W., Wenkel, R., Eichler, G., Paetzel, M., Schlüter, A. Magnetic resonance imaging. (2004) [Pubmed]
  12. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Staks, T., Schuhmann-Giampieri, G., Frenzel, T., Weinmann, H.J., Lange, L., Platzek, J. Investigative radiology. (1994) [Pubmed]
  13. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. Tombach, B., Bremer, C., Reimer, P., Matzkies, F., Schaefer, R.M., Ebert, W., Geens, V., Eisele, J., Heindel, W. AJR. American journal of roentgenology. (2002) [Pubmed]
  14. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Balzer, J.O., Loewe, C., Davis, K., Goyen, M., Leiner, T., Meaney, J.F., Pöckler-Schöniger, C., Schulte-Altedorneburg, G., Tombach, B., Vosshenrich, R., Wegener, R. European radiology. (2003) [Pubmed]
  15. Does a higher concentration of gadolinium chelates improve first-pass cardiac signal changes? Tombach, B., Reimer, P., Prümer, B., Allkemper, T., Bremer, C., Mühler, A., Heindel, W. Journal of magnetic resonance imaging : JMRI. (1999) [Pubmed]
  16. Interstitial magnetic resonance lymphography with gadobutrol in rats: evaluation of contrast kinetics. Fink, C., Bock, M., Kiessling, F., Delorme, S. Investigative radiology. (2002) [Pubmed]
  17. Comparison of 0.5-M Gd-DTPA with 1.0-M gadobutrol for magnetic resonance angiography of the supplying arteries of the spinal cord in thoracoabdominal aortic aneurysm patients. Nijenhuis, R.J., Gerretsen, S., Leiner, T., Jacobs, M.J., van Engelshoven, J.M., Backes, W.H. Journal of magnetic resonance imaging : JMRI. (2005) [Pubmed]
  18. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. Benner, T., Reimer, P., Erb, G., Schuierer, G., Heiland, S., Fischer, C., Geens, V., Sartor, K., Forsting, M. Journal of magnetic resonance imaging : JMRI. (2000) [Pubmed]
  19. Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso. Fink, C., Puderbach, M., Ley, S., Risse, F., Kuder, T.A., Bock, M., Thaler, J., Plathow, C., Kauczor, H.U. Journal of magnetic resonance imaging : JMRI. (2005) [Pubmed]
  20. X-ray digital subtraction angiography with 1 mol/L gadobutrol: results from a comparative porcine study With iodinated contrast agents. Kalinowski, M., Kress, O., Wels, T., Alfke, H., Klose, K.J., Wagner, H.J. Investigative radiology. (2002) [Pubmed]
  21. Interstitial MR lymphography using Gd-carrying liposomes. Misselwitz, B., Sachse, A. Acta radiologica. Supplementum. (1997) [Pubmed]
  22. Gadobutrol-enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: a prospective, multi-centre blinded comparison with digital subtraction angiography. Hentsch, A., Aschauer, M.A., Balzer, J.O., Brossmann, J., Busch, H.P., Davis, K., Douek, P., Ebner, F., van Engelshoven, J.M., Gregor, M., Kersting, C., Knüsel, P.R., Leen, E., Leiner, T., Loewe, C., McPherson, S., Reimer, P., Schäfer, F.K., Taupitz, M., Thurnher, S.A., Tombach, B., Wegener, R., Weishaupt, D., Meaney, J.F. European radiology. (2003) [Pubmed]
WikiGenes - Universities